Evidence map›Paper›PMID 26621543›Full record

ArticleCancer causes & control : CCC2016

Breast cancer risk factor associations differ for pure versus invasive carcinoma with an in situ component in case-control and case-case analyses.

Melanie Ruszczyk, Gary Zirpoli, Shicha Kumar, Elisa V Bandera, Dana H Bovbjerg, Lina Jandorf, Thaer Khoury, Helena Hwang, Gregory Ciupak, Karen Pawlish and 4 more

Abstract read
In one paragraph

Article in Cancer causes & control : CCC, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Overexpression ofOncoTargets and therapy · 2018
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 8 institutions in 1 country.

Melanie RuszczykDepartment of Biotechnical and Clinical Laboratory Sciences, University at Buffalo, 12 Capen Hall, Buffalo, NY, 14214, USA. mur@buffalo.edu.
Gary ZirpoliDepartment of Cancer Prevention and Control, Roswell Park Cancer Institute, Elm & Carlton Sts., Buffalo, NY, 14263, USA. gary.zirpoli@roswellpark.org.
Shicha KumarDepartment of Surgical Oncology, Roswell Park Cancer Institute, Elm & Carlton Sts., Buffalo, NY, 14263, USA. shicha.kumar@roswellpark.org.
Elisa V BanderaPopulation Science/Cancer Prevention and Control Program, Rutgers Cancer Institute of New Jersey, 195 Little Albany St., New Brunswick, NJ, 08903, USA. banderel@cinj.rutgers.edu.
Dana H BovbjergDepartment of Psychiatry, University of Pittsburgh Cancer Institute, 5150 Centre Ave., Pittsburgh, PA, 15232, USA. bovbjergdh@upmc.edu.
Lina JandorfDepartment of Oncology Sciences, Icahn School of Medicine at Mount Sinai, 1428 Madison Ave., New York, NY, 10029, USA. lina.jandorf@mssn.edu.
Thaer KhouryDepartment of Pathology, Roswell Park Cancer Institute, Elm & Carlton Streets, Buffalo, NY, 14263, USA. thaer.khoury@roswellpark.org.
Helena HwangDepartment of Pathology, University of Texas, Southwestern Medical Center, 5325 Harry Hines Blvd., Dallas, TX, 75390, USA. helena.hwang@utsouthwestern.edu.
Gregory CiupakDepartment of Cancer Prevention and Control, Roswell Park Cancer Institute, Elm & Carlton Sts., Buffalo, NY, 14263, USA. gregory.ciupak@roswellpark.org.
Karen PawlishNew Jersey State Cancer Registry, New Jersey Department of Health, 140 East Front Street, Trenton, NJ, 08625, USA. karen.pawlish@doh.state.nj.us.
Pepper SchedinDepartment of Cell, Development and Cancer Biology, Oregon Health Sciences University, 3181 SW Sam Jackson Pkwy, Portland, OR, 97239, USA. schedin@ohsu.edu.
Patricia Masso-WelchDepartment of Biotechnical and Clinical Laboratory Sciences, University at Buffalo, 12 Capen Hall, Buffalo, NY, 14214, USA. pmwelch@buffalo.edu.
Christine B AmbrosoneDepartment of Cancer Prevention and Control, Roswell Park Cancer Institute, Elm & Carlton Sts., Buffalo, NY, 14263, USA. christine.ambrosone@roswellpark.org.
Chi-Chen HongDepartment of Cancer Prevention and Control, Roswell Park Cancer Institute, Elm & Carlton Sts., Buffalo, NY, 14263, USA. chi-chen.hong@roswellpark.org.
Roswell Park Comprehensive Cancer Center · USUniversity at Buffalo, State University of New York · USIcahn School of Medicine at Mount Sinai · USNew Jersey Department of Health · USOregon Health & Science University · USRutgers Cancer Institute of New JerseyThe University of Texas Southwestern Medical Center · USUPMC Hillman Cancer Center · US

Funding

Two-Spirit Films in Indigenous Cancer HealthP30CA016056 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI MARK G FRATTINI · 1985 to 2026
$116.6M
TRANSCRIPTIONAL PROFILINGP30CA072720 · NCI · UNIV OF MED/DENT NJ-R W JOHNSON MED SCH · PI Chang S Chan · 1997 to 2026
$94.5M
Reproduction, Lactation and Hormonal Factors in Breast Cancer SubtypesP01CA151135 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI AMBROSONE, CHRISTINE B., OLSHAN, ANDREW · 2011 to 2017
$18.1M
NEW JERSEY CANCER PREVENTION & CONTROL PROGRAMU58DP003931 · DP · NEW JERSEY STATE DEPT/HEALTH/SENIOR SRVS · PI RODRIQUEZ, GLORIA · 2012 to 2014
$11.9M
Obesity, related comorbidities, and breast cancer outcomes in African AmericansR01CA185623 · NCI · RBHS -CANCER INSTITUTE OF NEW JERSEY · PI BANDERA, ELISA V, DEMISSIE, KITAW · 2014 to 2018
$6.2M
NSAIDs During Postpartum Involution for Breast Cancer ChemopreventionR01CA169175 · NCI · UNIVERSITY OF COLORADO DENVER · PI SCHEDIN, PEPPER J · 2013 to 2024
$4.8M
Race &Risk Factors for Early/Aggressive Breast CancerR01CA100598 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI AMBROSONE, CHRISTINE B. · 2004 to 2008
$4.8M
Obesity in ovarian cancer prognosisK22CA138563 · NCI · UNIV OF MED/DENT NJ-R W JOHNSON MED SCH · PI BANDERA, ELISA V · 2010 to 2012
$605k
Invasive breast cancer with and without DCIS: Race, risk factors and outcomesR03CA171061 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI AMBROSONE, CHRISTINE B., MASSO-WELCH, PATRICIA ANN · 2013 to 2014
$175k
EARLY THERAPEUTICS DEVELOPMENT WITH PHASE 2 EMPHASIS-261017106N01CA017106 · NCI · UNIVERSITY OF PENNSYLVANIA · 2002 to 2003
–
NCCDPHP CDC HHS 5U58DP003931-02NCCDPHP CDC HHS U58 DP003931NCI NIH HHS K22 CA138563NCI NIH HHS N01PC-2013-00021NCI NIH HHS P01 CA151135NCI NIH HHS P30 CA016056NCI NIH HHS P30 CA072720NCI NIH HHS R01 CA100598NCI NIH HHS R01 CA169175NCI NIH HHS R01 CA185623NCI NIH HHS R03 CA17106NCI NIH HHS R03 CA171061
6 · The paper itself

Abstract

purposeInvasive ductal carcinoma (IDC) is diagnosed with or without a ductal carcinoma in situ (DCIS) component. Previous analyses have found significant differences in tumor characteristics between pure IDC lacking DCIS and mixed IDC with DCIS. We will test our hypothesis that pure IDC represents a form of breast cancer with etiology and risk factors distinct from mixed IDC/DCIS.

methodsWe compared reproductive risk factors for breast cancer risk, as well as family and smoking history between 831 women with mixed IDC/DCIS (n = 650) or pure IDC (n = 181), and 1,620 controls, in the context of the Women's Circle of Health Study (WCHS), a case-control study of breast cancer in African-American and European-American women. Data on reproductive and lifestyle factors were collected during interviews, and tumor characteristics were abstracted from pathology reports. Case-control and case-case analyses were conducted using unconditional logistic regression.

resultsMost risk factors were similarly associated with pure IDC and mixed IDC/DCIS. However, among postmenopausal women, risk of pure IDC was lower in women with body mass index (BMI) 25 to <30 [odds ratio (OR) 0.66; 95 % confidence interval (CI) 0.35-1.23] and BMI ≥ 30 (OR 0.33; 95 % CI 0.18-0.67) compared to women with BMI < 25, with no associations with mixed IDC/DCIS. In case-case analyses, women who breastfed up to 12 months (OR 0.55; 95 % CI 0.32-0.94) or longer (OR 0.47; 95 % CI 0.26-0.87) showed decreased odds of pure IDC than mixed IDC/DCIS compared to those who did not breastfeed.

conclusionsAssociations with some breast cancer risk factors differed between mixed IDC/DCIS and pure IDC, potentially suggesting differential developmental pathways. These findings, if confirmed in a larger study, will provide a better understanding of the developmental patterns of breast cancer and the influence of modifiable risk factors, which in turn could lead to better preventive measures for pure IDC, which have worse disease prognosis compared to mixed IDC/DCIS.

Indexed as

Reproductive HistoryAdultBreast FeedingBreast NeoplasmsCarcinoma, Ductal, BreastCarcinoma, Intraductal, NoninfiltratingCase-Control StudiesFemaleHumansLogistic ModelsMiddle AgedMultivariate AnalysisObesityOdds RatioOverweightRisk FactorsBreast cancerCancer etiologyCancer pathologyDuctal carcinoma in situ componentRisk factors

Identifiers

PMID26621543
PMCPMC4724280
OpenAlexW2183120917

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.